{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:04Z","timestamp":1793119624798,"version":"4.5.0"},"reference-count":38,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022M3A9E4082647"],"award-info":[{"award-number":["NRF-2022M3A9E4082647"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2B5B02001602"],"award-info":[{"award-number":["NRF-2022R1A2B5B02001602"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,10,25]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Idiopathic pulmonary fibrosis (IPF) carries a high risk of lung cancer, but the effect of pirfenidone on lung cancer development remains uncertain. We investigated the association between pirfenidone use and lung cancer development in patients with IPF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 9938 patients with IPF from the Korean national claims database. Propensity score analysis with inverse probability of treatment weighting (IPTW) and landmark analyses were employed to evaluate lung cancer occurrence according to pirfenidone use. The association was evaluated using Cox regression models adjusted for clinical and socioeconomic variables. A single-centre IPF clinical cohort (n=941) was used for validating the findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean patient age was 69.4\u2005years, 73.7% were men and 32.1% received pirfenidone. Lung cancer developed in 766 patients with IPF (7.7%; 21.9 cases per 1000 person-years) during a median follow-up of 3.0\u2005years. After IPTW, the pirfenidone group showed lower incidence (10.4<jats:italic>versus<\/jats:italic>27.9 cases per 1000 person-years) than the no pirfenidone group. Landmark analysis at 6\u2005months after IPF diagnosis also showed lower incidence of lung cancer in the pirfenidone group than in the no pirfenidone group. Pirfenidone use was independently associated with a reduced lung cancer risk (weighted adjusted hazard ratio (HR) 0.347, 95% CI 0.258\u20130.466). A clinical cohort showed similar association (weighted adjusted HR 0.716, 95% CI 0.517\u20130.991). The association persisted across subgroups defined by age or sex.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pirfenidone use may be associated with a reduced lung cancer risk in patients with IPF.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.01484-2024","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:10:20Z","timestamp":1730995820000},"page":"2401484","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study"],"prefix":"10.1183","volume":"65","author":[{"given":"Hee-Young","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoseob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonjong","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-3522","authenticated-orcid":false,"given":"Jin Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"2025022702500547000_65.2.2401484.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025022702500547000_65.2.2401484.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751"},{"key":"2025022702500547000_65.2.2401484.3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4046\/trd.2018.0091","article-title":"Korean guidelines for diagnosis and management of interstitial lung diseases: part 2. Idiopathic pulmonary fibrosis","volume":"82","author":"Lee","year":"2019","journal-title":"Tuberc Respir Dis"},{"key":"2025022702500547000_65.2.2401484.4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030593"},{"key":"2025022702500547000_65.2.2401484.5","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201807-481OC"},{"key":"2025022702500547000_65.2.2401484.6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12890-019-0905-8","article-title":"Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"19","author":"Yoo","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025022702500547000_65.2.2401484.7","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3760\/cma.j.issn.0366-6999.20141346","article-title":"Idiopathic pulmonary fibrosis will increase the risk of lung cancer","volume":"127","author":"Li","year":"2014","journal-title":"Chin Med J"},{"key":"2025022702500547000_65.2.2401484.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81591-z"},{"key":"2025022702500547000_65.2.2401484.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.11.010"},{"key":"2025022702500547000_65.2.2401484.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07494-w"},{"key":"2025022702500547000_65.2.2401484.11","doi-asserted-by":"crossref","first-page":"960316","DOI":"10.1155\/2011\/960316","article-title":"Postoperative acute exacerbation of IPF after lung resection for primary lung cancer","volume":"2011","author":"Watanabe","year":"2011","journal-title":"Pulm Med"},{"key":"2025022702500547000_65.2.2401484.12","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/1759-7714.14121","article-title":"Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows","volume":"12","author":"Takahara","year":"2021","journal-title":"Thorac Cancer"},{"key":"2025022702500547000_65.2.2401484.13","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1038\/s41598-021-87747-1","article-title":"Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2025022702500547000_65.2.2401484.14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40248-018-0150-7","article-title":"Prevalence, risk factors, and impact of lung cancer on outcomes of idiopathic pulmonary fibrosis: a study from the Middle East","volume":"13","author":"Mohamed","year":"2018","journal-title":"Multidiscip Respir Med"},{"key":"2025022702500547000_65.2.2401484.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050004"},{"key":"2025022702500547000_65.2.2401484.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.049"},{"key":"2025022702500547000_65.2.2401484.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-218281"},{"key":"2025022702500547000_65.2.2401484.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2017.09.007"},{"key":"2025022702500547000_65.2.2401484.19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1032-6"},{"key":"2025022702500547000_65.2.2401484.20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3904\/kjim.2023.273","article-title":"Mechanical ventilation in patients with idiopathic pulmonary fibrosis in Korea: a nationwide cohort study","volume":"39","author":"Sim","year":"2024","journal-title":"Korean J Intern Med"},{"key":"2025022702500547000_65.2.2401484.21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12890-023-02373-z","article-title":"Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study","volume":"23","author":"Joung","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2025022702500547000_65.2.2401484.22","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025022702500547000_65.2.2401484.23","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181484347"},{"key":"2025022702500547000_65.2.2401484.24","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2014.38.5.395"},{"key":"2025022702500547000_65.2.2401484.25","doi-asserted-by":"crossref","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","article-title":"Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"2025022702500547000_65.2.2401484.26","doi-asserted-by":"crossref","first-page":"2001877","DOI":"10.1183\/13993003.01877-2020","article-title":"Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis","volume":"57","author":"Yoon","year":"2021","journal-title":"Eur Respir J"},{"key":"2025022702500547000_65.2.2401484.27","unstructured":"Faries DE , Leon AC , Haro JM , et al. Analysis of Observational Health Care Data Using SAS. Cary, SAS Institute Cary, 2010."},{"key":"2025022702500547000_65.2.2401484.28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab158"},{"key":"2025022702500547000_65.2.2401484.29","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025022702500547000_65.2.2401484.30","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"2025022702500547000_65.2.2401484.31","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fonc.2019.01550","article-title":"The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC","volume":"9","author":"Marwitz","year":"2019","journal-title":"Front Oncol"},{"key":"2025022702500547000_65.2.2401484.32","doi-asserted-by":"crossref","first-page":"10900","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci Rep"},{"key":"2025022702500547000_65.2.2401484.33","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0328TR"},{"key":"2025022702500547000_65.2.2401484.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200501-017PP"},{"key":"2025022702500547000_65.2.2401484.35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.688625"},{"key":"2025022702500547000_65.2.2401484.36","doi-asserted-by":"crossref","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol"},{"key":"2025022702500547000_65.2.2401484.37","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S224007"},{"key":"2025022702500547000_65.2.2401484.38","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2169\/internalmedicine.0559-17","article-title":"The efficacy and safety of long-term pirfenidone therapy in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Ogawa","year":"2018","journal-title":"Intern Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01484-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:50:39Z","timestamp":1740653439000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01484-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1183\/13993003.01484-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01484-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}